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Cordycepin is a natural pure compound extracted from Cordyceps sinensis (CS). We have demonstrated that CS stimulates
steroidogenesis in primary mouse Leydig cell and activates apoptosis in MA-10 mouse Leydig tumor cells. It is highly possible
thatcordycepin is the main componentin CS modulatingLeydig cell functions. Thus, our aim was to investigate the steroidogenic
andapoptoticeﬀectswithpotentialmechanismofcordycepin onMA-10mouseLeydigtumorcells.Resultsshowedthatcordycepin
signiﬁcantly stimulated progesterone production in dose- and time-dependent manners. Adenosine receptor (AR) subtype
agonists were further used to treat MA-10 cells, showing that A1,A 2A,A 2B,a n dA 3, AR agonists could stimulate progesterone
production. However, StAR promoter activity and protein expression remained of no diﬀerence among all cordycepin treatments,
suggesting that cordycepin might activate AR, but not stimulated StAR protein to regulate MA-10 cell steroidogenesis. Meanwhile,
cordycepin could also induce apoptotic cell death in MA-10 cells. Moreover, four AR subtype agonists induced cell death in a
dose-dependent manner, and four AR subtype antagonists could all rescue cell death under cordycepin treatment in MA-10 cells.
In conclusion,cordycepin could activate adenosine subtype receptors and simultaneouslyinduce steroidogenesis and apoptosis in
MA-10 mouse Leydig tumor cells.
1.Introduction
Cordycepssinensis(CS)isaningredientoftraditionalChinese
medicine and is prescribed for replenish the kidney and
soothe the lung and for the treatment of fatigue [1].
Cordycepin (3 -deoxyadenosine, an adenosine analogue) is
a pure component extracted from the mycelia of CS, and
it is well known to possess anticancer ability which induce
apoptosis in HeLa cells, oral cancer cells, breast cancer cells,
leukemia, and lymphoma cell lines [2–5]. Previous studies
demonstrated that CS alone could stimulate steroid produc-
tion in both normal and tumor mouse Leydig cells [6, 7]a n d
activate apoptosis in MA-10 mouse Leydig tumor cells [8].
It is highly possible that cordycepin is the main component
in CS modulating Leydig cell functions. Thus, the aim of
the present study was to investigate the steroidogenic and
apoptotic eﬀects with potential mechanism of cordycepinon
MA-10 mouse Leydig tumor cells.
Steroidogenesis, steroid hormone biosynthesis, occurs
mainly in the adrenal glands, brain, placenta, testes, and
ovaries [9]. In the male reproduction system, steroidoge-
nesis in Leydig cells is regulated by luteinizing hormone
(LH)/human chorionic gonadotropin (hCG). LH and hCG
activate its cognate receptors and coupling to the adenylate
cyclase (AC) throughthe heterotrimeric guanine nucleotide-
binding regulatory protein (G-protein) [10, 11]. The acti-
vated GTP-bound α subunit of G-protein would be able
to activate adenylyl cyclase, which results in the hydrolysis
of ATP to cyclic AMP. Once cAMP is synthesized, the
following activation of protein kinase A (PKA) pathway
would phosphorylate steroidogenic acute regulatory protein
(StAR) [12]. The StAR protein, a 30kDa phosphoprotein,
is the rate-limiting step which delivers cholesterol from the
outer to the inner mitochondrial membrane [13]. After
translocation into mitochondrial, P450 side chain cleave
enzyme (P450scc)convertscholesteroltopregnenolone[14].
When pregnenolone is formed, it may be metabolized to
progesterone by mitochondrial 3β-hydroxysteriod dehydro-
genase (3β-HSD), or it may exit the mitochondria and
undergo further metabolism with the ﬁnal steroid hormone
product dependent upon the nature of the tissue [15, 16].
It has been well demonstrated that adenosine acts
through four G-protein-coupled membrane receptors, the
A1,A 2A,A 2B,andA 3 adenosinereceptors[17].Theadenosine2 Evidence-Based Complementary and Alternative Medicine
A1 and A3 receptors (A1-AR and A3-AR) inhibit adenylate
cyclase via Gi and activate phospholipase C (PLC) [18, 19],
and the adenosine A2A and A2B receptors (A2A-AR and A2B-
AR) stimulate adenylyl cyclase via Gs [20, 21], respectively.
It is also shown that adenosine appears to induce cell death
through apoptosis, whereas ATP appears to cause both
necrosis and apoptosis [22].
Although some reports have showed that cordycepin
possesses anticancer ability, there is still no research about
cordycepin on gonadal steroidogenesis. In fact, we have
demonstrated that cordycepin could stimulate testosterone
production in normal mouse primary Leydig cells without
any phenomenon of cell death [23]. Since the isolation
of primary Leydig cell is complicated with very low yield
from mouse testis, MA-10 mouse Leydig tumor cell line was
then used to further examine the regulatory mechanisms
regarding the eﬀects of cordycepin. Interestingly, we did ﬁnd
that cordycepincould induceMA-10 cell steroidogenesisand
apoptosis. Thus, our objective was to investigate the eﬀect of
cordycepin on Leydig cell steroidogenesis and apoptosis with
the preliminarily possible mechanisms.
2.Materialsand Methods
2.1. Chemicals. Cordycepin, bovine serum albumin (BSA),
Waymouth MB 752/1 medium, N6-cyclopentyladenosine
(CPA), 2-p-(2-carboxyethyl) phenethylamino-5 -N-ethyl-
carboxamidoadenosine (CGS-21680), 5 -N-ethylcarbox-
amidoadenosine (NECA), N6-(3-iodobenzyl) adenosine-
5 -N-methyluronamide (IB-MECA), 8-Cyclopentyl1,3-di-
propylxanthine (DPCPX), 8-(3-Chlorostyryl) caﬀeine (CSC),
8-[4-[((4-Cyanophenyl)carbamoylmethyl)oxy]phenyl]-1,3-
di(n-propyl) xanthine (MRS 1754), 3-Ethyl-5-benzyl-2-
methyl-4-phenylethylethynyl-6-phenyl-1,4-dihydropyri-
dine-3,5-dicarboxylate (MRS 1191), human chorionic
gonadotropin (hCG) (10,000IU per gram) and methyl-
thiazolecterazoli-um (MTT) were purchased from Sigma
Chemical (St. Louis, mo, USA). Fetal bovine serum
(FBS), Dulbecco’s phosphate-buﬀered saline, lyophilized
trypsin-EDTA, and gentamicin sulfate were purchased
from Gibco (Grand Island, NY, USA). Sodium hydroxide,
hydrochloric acid, Sodium dodecyl sulfate (SDS), sucrose,
EDTA, isopropyl alcohol, chloroform, and Tween 20 were
purchased from Merck (Darmstadt, Germany). Tris base
was purchased from Calbiochem (San Deigo, Calif, USA).
Acrylamide was purchased from J.T. Baker (Phillipsburg,
NJ, USA). HEPES was purchased from Mallinckrodt Baker,
Inc. (Paris, USA). Tissue culture grade sodium bicarbonate,
sodium carbonate, sodium chloride, sodium dihydrogen
phosphate, and potassium chloride were purchased from
Riedel-deHaen (Seelze, Germany). dNTP and MMLV
reverse transcriptase were purchased from Promega
(Madison, Wis, USA). Taq was purchased from ABgene
(Surrey, UK). Donkey antirabbit IgG conjugated with
horseradish peroxidase were purchased from Amersham
International (Arlington Heights, Ill, USA). Antibody
against β-actin was purchased from Cell Signaling (Beverly,
USA). Antibody against StAR was a generous gift from Dr.
Strauss (University of Pennsylvania Medical Center, USA).
Charcoal was purchased from Showa Chemical Inc. (Tokyo,
Japan). [3H] progesterone used for radioimmunoassay was
purchased from Dupont-New England Nuclear (Boston,
USA). Antiserum to progesterone was a kind gift from Dr.
Paulus S. Wang (National Yang Ming University, Taipei,
Taiwan).
2.2. Cell Culture. The MA-10 cell line was a gift from Dr.
Mario Ascoli (The UniversityofIowa, Iowa City,USA)and is
maintained at 37◦C in a humidiﬁed environment containing
95% air and 5% CO2 for all the following experiments.
MA-10 cells (5 × 103 cells/100μLm e d i u m )o r( 6× 105
cells/2mL medium) were plated into 96-well plates or 6cm
dish grown for 24hr in Waymouth medium containing 10%
fetal bovine serum, respectively. The medium was removed
and the cells were washed twice with 1X PBS, and then
treated with various concentrations of cordycepin in serum
free Waymouth medium for indicated time periods. The
cells were then isolated for total protein. The expression
of target protein was determined by Western blot analysis.
Cytotoxicity assay and cell morphological analysis of the
MA-10 cells were determined by MTT assay. The media
were withdrawn and progesterone levels were determined by
radioimmunoassay. Finally, the adenosine receptor subtypes
mRNA expression were performed by RT-PCR.
2.3. Morphology Study. MA-10 cells were seeded in 96-well
plate (Techno Plastic Products AG, Trasadingen, Switzer-
land) containing 5 × 103 cells with 100μL serum medium in
each well. After 70–80% conﬂuence, cells were treated with-
out or with 100μMa n d1m Mc o r d y c e p i nf o r2 4h r ,r e s p e c -
tively. Cell morphology was then observed and recorded
under light microscopy (Olympus, CK40). Apoptosis was
characterized by the loss of cellular contact with the matrix
and the appearance of plasma membrane blebbing.
2.4. MTT Cytotoxicity Assay. Cordycepin-induced MA-10
cells cytotoxicity was determined by measuring mitochon-
drial succinate dehydrogenase activity using a modiﬁcation
of the MTT assay. After MA-10 cells reach 70%–80% conﬂu-
ence, cells were treated with serum free medium containing
100μM and 1mM cordycepin for indicated time points
(24 and 48hr). MTT was added to wells (0.5mg/mL ﬁnal
concentration) after time points of culture at 37◦Ci na5 %
CO2 humidiﬁed atmosphere in the presence of the desired
reagents. Mitochondrial dehydrogenases of viable cells will
convert MTT into a color-dense formazan. Four hours later,
the DMSO was added in wells to dissolve the formazan.
The DMSO solutions were added and the absorbance was
measured at 590nm by an ELISA reader (VersaMax, MDS
Inc., Toronto, Canada).
2.5. DNA Fragmentation Assay. Cells (1 × 106) were lysed
in a 0.6mL cell lysis solution containing 20mM Tris-HCl,
10mM EDTA, pH 8.0 and 0.3% Triton X-100. DNA was
extracted with 0.6mL phenol/chloroform (1:1), and the
mixture was centrifuged at 12,500rpm for 10min. DNA in
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(1:1) again. The aqueous (DNA containing) phase was
mixed with isopropanol at −20◦Co v e r n i g h t .A f t e rc e n -
trifugation, DNA pellets were washed with 70% ethanol
and air-dried. DNA pellets were dissolved in TE buﬀer
(10mM Tris-HCl, 1mM EDTA, pH 8.0), and RNase A
(3mg/mL) was added to remove RNA at 37◦Cf o r3 0m i n .
DNA electrophoresis was carried out in 2% agarose gel. The
gelwas stained withethidiumbromide.DNAfragments were
visualized by exposing the gel to UV light.
2.6. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR). Total RNAwas isolated from MA-10 cells using Trizol
reagent as recommended by the manufacturer (Invitrogen,
Carlsbad, Calif, USA). Reverse transcription was performed
in a mixture containing5μM randomprimer, 200μMd NT P ,
2U/μL MMLV reverse transcriptase together with 5μLt R N A
as the template. The corresponding buﬀer was performed
at 42◦C for 90min followed by 95◦Cf o r1 0 m i n .P C R
was performed in a mixture containing 2μL 10X PCR
buﬀer, 0.4μL1 0m Md N T P ,0 . 4μL2 0m Ms p e c i ﬁ cf o r w a r d
and reverse primers (primer sequence and corresponding
sequence of speciﬁc genes were listed in Table 1), 14.7μL
ddH2O, 0.1 μL0 . 5UT a qw i t h2μL RT product as template
for each reaction. Thermocontrolling program was set up as
the following: denature at 95◦C for 30sec, annealing at 55◦C
for 30sec, elongation at 72◦C for 30sec with another 5min
of elongation at 72◦C .T h ew h o l em i x t u r ew a ss u b j e c t e dt o
30 cycles for ampliﬁcation of L19, 32 cycles for ampliﬁcation
of A1-AR, 34 cycles for ampliﬁcation of A2A-AR and A2B-AR
and 38 cycles for ampliﬁcation of A3-AR. The PCR product
was then separated on a 1.5% agarose gel at 120V for 30min
in 1X TBE buﬀer (0.09M Tris, 0.09M boric acid, 0.001M
EDTA, pH 8.0). The gel was then stained with ethidium
bromidefor 10min and destained with mili-Q water. The gel
imagewas capturedbyusingLabworkimager system(Digital
CCD Camera, Hamamtsu Photonics system, Bridgewater,
USA).
2.7. Radioimmunoassay (RIA). Media from cultures with
diﬀerent treatments were harvested. Twenty μLo fs a m p l e
was loaded into a glass tube and 100μLe a c ho fp r o g e s t e r o n e
antiserum and 3H progesterone were loaded. Equilibrium
reaction occurred at 37◦C for 30min and was stopped by
putting the tubes in ice. Charcoal was added into the tubes
at 4◦Cf o r1 5 m i na n dc e n t r i f u g e df o r1 0 m i ni no r d e r
to spin down the charcoal-3H progesterone complex. The
supernatant was poured into 2mL of scintillation ﬂuid and
samples would be counted in a β-counter (LS 5000TA,
Beckman Inc., Fullerton, Calif, USA).
2.8. Immunoblot Analysis. 6.0 × 105 cells were cultured
in 6cm dish. After treatment, cells were rinsed with cold
PBS. Then, the cells were harvested by 100μLl y s i sb u ﬀer
(20mM Tris-base, 150mM NaCl,1mM EDTA,1mM EGTA,
1% Triton X-100, 2.5mM Sodium pyrophosphate, 1mM
beta-Glycerolphosphate, 1mM Na3VO4). The cell lysate was
subjected to centrifugation at 12,000×gf o r1 2m i na t4 ◦C.
The supernatant was stored at −20◦Cu n t i lu s e d .T h e
Table 1:Sequenceofprimersusedforreversetranscription-polym-
erase chain reaction (RT-PCR).
Sequence (5  to 3 )P C R s i z e
L19 F GAA ATC GCC AAT GCC AAC TC
R TCT TAG ACC TGC GAG CCT CA 405 b.p.
A1-AR
F CGG GAT CCT ACA TCT CGG CCT TCC
AGG
R GGA ATT CAG TAG GTC TGT GGC
CCA ATG
219 b.p.
A2A-AR
F CGG GAT CCG TCC CTG GCC ATC ATC
GT
R GGA ATT CGA TCC TGT AGG CGT
AGA T
177 b.p.
A2B-AR
F CGG GTA CCC CTC GAG TGC ATT ACA
GA
R CCG CCG AAA CCT TTA TAC CTG AGC
216 b.p.
A3-AR
F CGG GAT CCC GTT CCG TGG TCA
GTT TGR GGA ATT CGC AGG CGT AGA
CAA TAG G
384 b.p.
protein concentration was determined by Lowry method
[24]. Total proteins were separated in 12.5% SDS-PAGE.
Electrophoresis was performed in SDS-PAGE running buﬀer
(24mM Tris/HCl, 0.19M glycine, 0.5% SDS, pH 8.3).
The proteins were transferred to polyvinylidene diﬂuoride
membranes (PVDF) in transfer buﬀer (20mM Tris/HCl,
150Mm glycine, 10% methanol, 0.05% SDS). The PVDF
membrane with protein on it was incubated in blocking
buﬀer (TBS buﬀer containing 5% Carnation non-fat dry
milk and 0.1% Tween-20) at room temperature for an hour.
Afterwashing,themembranewouldbeincubatedinprimary
antibodies StAR at 1:2500 dilutions overnight at 4◦C. The
membrane would be washed three times (10min each) with
TBS containing 0.1% Tween-20. It was then incubated for
an hour at room temperature with fresh blocking buﬀer
containing the secondary antibody, antirabbit IgG. The
membrane was washed and the signal detected by using the
Renaissance chemiluminescencereagent.The desiredprotein
was quantitatedbyUVP EC3Imaging System(Upland,Calif,
USA). The amount of β-actin in each lane was detected and
quantiﬁed as well in order to normalize the expression of
target protein.
2.9. Transient Transfection and Luciferase Assays. The 5 -
ﬂanking regions (−1278/+32) of the mouse StAR gene
were cloned into the pGL3 basic vector (Promega Corp.,
Madison, Wis, USA), upstream of a luciferase reporter gene
utilizing the XhoI and HindIII sites. The plasmid pSV-
Galactosidase control vector (Promega Corp.) was used to
normalize transfection eﬃciency. Plasmids were transfected
using Lipofectamine 2000 (Invitrogen 11668-019,Invitrogen
Corp., Calif, USA). In brief, 1.2 × 105 cells/500μLm e d i u m
were cultured in either 24-well plates to 65–75% conﬂuency
and transfected using 0.5μg of plasmid in the presence
of 0.5μgo fpSV-Galactosidase control vector. After 6hr
of transfection, MA-10 cells were followed by rising and
incubationinserum-free Waymouthmediumfor18hr.After4 Evidence-Based Complementary and Alternative Medicine
medium was changed, cells were then treated with cordy-
cepin for another 12hr. Luciferase assays were performed
using the Luciferase Reporter Assay System according to
the manufacturer’s instructions (Promega Corp., Madison,
Wis, USA). Brieﬂy, after treatment cells were washed with
1X PBS and 200μL of the 1X passive lysis buﬀer (Dual-
Luciferase Reporter Assay System, Promega E1910, Promega
Corp., Madison, Wis, USA) was added to the plates. The
cellular debris was pelleted by centrifugation at 12,000×g
at 4◦C, and the 20μL supernatant was measured for 50μL
Luciferase Assay Buﬀer (Dual-Luciferase Reporter Assay
System, Promega E1910, Promega Corp., Madison, Wis,
USA) in a MiniLumat Luminometer (Turner Designs Corp.,
Sunnyvale, Calif, USA).
2.10.Statistical Analysis. Eachdatapointintheﬁguresrepre-
sents the mean ± SEM of three orfour separate experiments.
Statistically signiﬁcant diﬀerences between treatments and
controls were determined by one-way ANOVA and then
least signiﬁcance diﬀerence (LSD) or with t-test comparison
procedure. Statistical signiﬁcance was set at P<. 05.
3.Results
3.1. Eﬀects of Cordycepin on Steroidogenesis in MA-10 Mouse
Leydig Tumor Cells. To test the hypothesis that cordycepin
inﬂuences the production of steroid hormone in MA-10
mouse Leydig tumor cells; we initially determined the eﬀect
of cordycepin on the production of progesterone. MA-10
cells were incubated with diﬀerent dosages (1, 10, 100μM,
and 1mM) of cordycepin for 24hr. Results showed that
the progesterone production induced by 100μMc o r d y c e p i n
was more than 3 folds signiﬁcantly compared to the control
(217.5 ± 101.7 versus 675.9 ± 185.4pg/μgp r o t e i n ;P<. 05)
(Figure 1(a)).AsshowninFigure 1(b),cordycepinat100μM
signiﬁcantly stimulated progesterone to a maximum at 24hr
(P<. 05). According to the results, 100μM cordycepin for
24hr treatment was used to investigate the possible cellular
mechanism.
3.2. RT-PCR Analysis for Detection of A1,A 2A,A 2B,a n d
A3 Adenosine Receptor mRNA Transcripts in MA-10 Mouse
Leydig Tumor Cells. It has been reported that cordycepin
could inhibit lung carcinoma and melanoma cell growth
by stimulating A3-AR [25, 26]. We hypothesized for the
presence of functional adenosine receptor subtypes that
involved in cordycepin-induced steroidogenesis in MA-10
cells. Thus, mRNA expressions of all four AR subtypes,
A1,A 2A,A 2B,a n dA 3, with cordycepin treatment in MA-
10 cells were analyzed by RT-PCR. The results showed
that cordycepin (100μM and 1mM) could change the
mRNA expression among four AR subtypes (Figure 2(a)).
The normalized results showed that the treatment of 1mM
cordycepin for 24hr upregulated the expression of A1-AR
mRNAforabout1.5fold(P<. 05)(Figure 2(b)).Cordycepin
(1mM) upregulated the expression of A2A-AR mRNA for
about 2 folds (P<. 05) (Figure 2(c)). Cordycepin at 1mM
would also upregulate the expression of A3-AR mRNA for
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Figure 1: Dose- and time-course eﬀects of cordycepin on steroido-
genesis in MA-10 mouse Leydig tumor cells. MA-10 cells (5000
cells/well) were treated with 1, 10, 100μMa n d1 m Mc o r d y c e p i n
for 24hr (a); and MA-10 cells were treated with 100μMc o r d y c e p i n
f o r0 ,1 ,3 ,6 ,a n d2 4 h r( b ) ,r e s p e c t i v e l y .T r e a t m e n to fh C G
(1IU) was used as a positive control. Media were collected and
assayed for progesterone production by RIA. Each data point in the
ﬁgure represents the mean the mean ± SEM of three independent
experiments with triplicates in each treatment. Asterisk ∗(P<
.05) above the bars indicates signiﬁcant diﬀerence compared with
control.
about 3 folds (P<. 05) (Figure 2(e)). However, both
100μM and 1mM cordycepin would downregulate A2B-AR
mRNA expression by 60% and 80%, respectively (P<. 05)
(Figure 2(d)).
3.3. A1,A 2A,A 2B,a n dA 3 AR Were Involved in Cordycepin-
Induced Steroidogenesis in MA-10 Mouse Leydig Tumor Cells.
By using AR agonists (1∼100μM) to treat MA-10 cells for
24hr, the results showed that A1-, A2A-, A2B-, and A3-
AR agonists could stimulate progesterone production in
MA-10 mouse Leydig cells (P<. 05) (Figures 3(a)–3(d)).
Compared to the control, A1-AR agonist could signiﬁcantly
stimulate progesterone production and reach 4.1 folds by
100μMC P A( P<. 05) (Figure 3(a)). A2A-AR agonist
could signiﬁcantly stimulate progesterone production and
reach 6.8 and 7.9 folds by 10 and 25μM CGS-21680,
respectively, (P<. 05) (Figure 3(b)). A2B-AR agonist couldEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Characterization of A1,A 2A,A 2B,a n dA 3 AR mRNA expression in MA-10 mouse Leydig tumor cells. MA-10 cells (1× 106)w e r e
cultured inWaymouthmediumto80%conﬂuence,andthenthetotalRNA were extracted andtheexpression ofadenosinereceptor subtypes
mRNA were analyzed by RT-PCR. (a) shows A1,A 2A,A 2B,a n dA 3 AR mRNA expression in response to cordycepin at diﬀerent dosages
(100μMand1mM)for24hr .L19 is the housekeeping gene used as an internal control. (b) shows the integrated optical density (IOD) of
A1,A 2A,A 2B,a n dA 3 AR mRNA expression after normalizationwith L19. Each data point in the ﬁgure represents the mean ± SEM of three
separate experiments. Asterisk ∗(P<. 05) above the bars indicates signiﬁcantdiﬀerence compared with control.
signiﬁcantly stimulate progesterone production and reach
7.6, 8.9, and 9.8 folds by 1, 10, and 100μMN E C A ,
respectively, (P<. 05) (Figure 3(c)). A3-AR agonist could
signiﬁcantly stimulate progesterone production and reach
10.5 and 24.7 folds by 10 and 50μM IB-ECA, respectively
(P<. 05) (Figure 3(d)). On the other hand, cordycepin
(100μM) cotreated with A1-AR agonist would signiﬁcantly
decrease CPA-stimulated (100μM) progesterone production
by 47% (P<. 05) (Figure 3(a)). Cordycepin (100μM)
cotreated with A2B-AR agonist would signiﬁcantly decrease
NECA-stimulated (1, 10 and 100μM) progesterone pro-
duction by 70%, 69%, and 47%, respectively, (P<. 05)6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: A1,A 2A,A 2B,a n dA 3 AR are involved in cordycepin-induced steroidogenesis. MA-10 cells (5000 cells/well) were treated with
diﬀerent dosage (1∼100μM) of A1,A 2A,A 2B,a n dA 3 AR agonists,which were (a) CPA, (b) CGS-21680, (c) NECA, and (d) IB-MECA in the
absence or presence of 100μM cordycepin for 24hr. Media were collected and assayed for progesterone production by RIA. Each data point
in the ﬁgure represents the mean the mean ± SEM of three independent experiments with triplicates in each treatment. Asterisk ∗(P<. 05)
above the bars indicates signiﬁcant diﬀerence compared with control.
(Figure 3(c)). Cordycepin (100μM) cotreated with A3-AR
agonist would signiﬁcantly decrease IB-MECA (50μM)-
stimulated progesterone production by 33% (P<. 05)
(Figure 3(d)). However, cordycepin (100μM) cotreated with
A2A-AR agonist would not aﬀect CGS-21680-stimulated
progesterone production (P>. 05) (Figure 3(b)). These
results demonstrated that cordycepin could regulate AR
subtype expressions to stimulate progesterone production
in MA-10 cells. To further understand the mechanism of
functional AR subtypes that involved in the cordycepin-
inducedsteroidogenesisinMA-10mouse Leydig tumorcells,
selective A1-, A2A-, A2B-, and A3-AR subtype antagonists
(10nM∼1μM) were used to cotreat with cordycepin for
24hr. The results showed that A1-, A2A-, A2B-, and A3-AR
antagonists did not have inhibitory eﬀect on cordycepin-
induced progesterone production in MA-10 cells (P>. 05)
(Figures 4(a)–4(d)).
3.4. Eﬀects of Cordycepin on StAR Protein and Promoter
Expressions in MA-10 Mouse Leydig Tumor Cells. It has
been previously shown that steroidogenesis induced by
Cordycep sinensis in MA-10 cells requires de novo protein
synthesis [27]. To further understand the mechanism of
cordycepin-induced steroidogenesis in MA-10 cells, StAR
protein expression was investigated by Western blotting
analysis. MA-10 cells were incubated with diﬀerent dosages
(1∼100μM) of cordycepin for 3hr or 100μMc o r d y c e p i n
for 1, 3, 6, and 12hr, respectively. Results showed that the
expression of StAR protein was not activated by cordycepin
with diﬀerent dosages (Figure 5(a))a n dd i ﬀerent time
treatments (Figure 5(b))inMA-10mouse Leydigtumorcells
(P>. 05).
In addition, MA-10 cells were transiently transfected
with plasmid containing luciferase gene with 5 -ﬂanking
StAR promoter constructs between −1.3k to +32 regions,
and cordycepin (100μM) was added for 12hr treatment.
Results of 5 -deletion promoter analysis indicated that
cordycepin didnot increase StAR promoteractivity (P>. 05)
(Figure 5(c)). Taken together, these results suggest that StAR
protein and StAR promoter might not be involved in the
cordycepin-induced steroidogenesis in MA-10 cells.
3.5. Eﬀects of Cordycepin and Adenosine on Cell Death in MA-
10 Mouse Leydig Tumor Cells. According to our previousEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Eﬀects of AR antagonists on cordycepin-induced steroidogenesis in MA-10 mouse Leydig tumor cells. MA-10 cells (5,000
cells/well) were treated with diﬀerent dosage(10nM∼1μM) ofA1,A 2A,A 2B,andA 3 ARantagonists,whichwere (a)DPCPX, (b)Caﬀeine,(c)
MRS-1754,and(d) MRS-1191in the absence orpresence of100μM cordycepin for24hr. Media were collected and assayedforprogesterone
production by RIA. Each data point in the ﬁgure represents the mean the mean ± SEM of three independent experiments with triplicates in
each treatment. Asterisk ∗(P<. 05) above the bars indicates signiﬁcantdiﬀerence compared with control.
studies, cordycepin has antitumor activity in OECM-1 oral
cancer and MA-10 mouse Leydig tumor cell lines [3, 28].
We hypothesized that cordycepin, an adenosine analogue,
might act through AR to induce cell death in MA-10 mouse
Leydig tumor cells. Thus, the death eﬀects of cordycepin and
adenosine on MA-10 cell line was investigated by culturing
MA-10 cells with diﬀerent dosage of adenosine (10μM∼
10mM) and cordycepin (100μM∼1mM) for comparison.
MTT assay showed that 1, 2, 5, and 10mM adenosine
signiﬁcantly decreased MA-10 cell viability to 78%, 65%,
43%, and 39% (P<. 05), and cordycepin (100μMa n d
1mM) signiﬁcantly decreased MA-10 cell viability to 44%
and 13% (P<. 0 5 )f o r4 8 h rt r e a t m e n t ,r e s p e c t i v e l y
(Figure 6(a)). DNA fragmentation was also observed in the
MA-10 cells with 10mM adenosine after 48hr treatment
(Figure 6(b)). The results are comparable regarding the cell
death eﬀects between cordycepin and adenosine on MA-10
cells.
3.6. A1,A 2A,A 2B,a n dA 3 AR Were Involved in Cordycepin-
Induced Cell Death in MA-10 Mouse Leydig Tumor Cells.
Previous data demonstrate that expressions of AR subtypes,
A1,A 2A,A 2B,a n dA 3 mRNA are found in MA-10 cells,
and their expression could be modulated by the presence
of cordycepin. To investigate whether cordycepin-induced
apoptosis was mediated via adenosine receptors on MA-10
mouse Leydig tumor cells, cells were treated with A1-, A2A-,
A2B-, and A3-AR agonists (CPA, CGS-21680, NECA and IB-
MECA) for 24hr, respectively. Results show that some MA-
10 cells appeared rounded-up phenomenon with ﬂoating
and membrane-blebbing after 24hr cordycepin (100μM
and 1mM) treatment (Figure 7(a)). In addition, MA-10
cells treated with A1-, A2A-, A2B-, and A3-AR agonists
(100μM, 25μM, 100μM, and 50μM ,r e s p . )f o r2 4 h ra l s o
inducedcells tohave rounded-up phenomenonwith ﬂoating
cells (Figure 7(b)). Cotreatment of cordycepin (100μMa n d
1mM) with A 1-, A2A-, and A2B-agonists (100μM, 25μM,
and 100μM ,r e s p . )f o r2 4h ri n d u c e dc e l l st oh a v er o u n d e d -
up phenomenon with ﬂoating and membrane-blebbing.
Interestingly, A3-AR agonist (50μM) cotreated with cordy-
cepin (100μM and 1mM) for 24hr would let some MA-
10 cell recover back to polygonal shape, which was similar
to the control group (Figure 7(c)). MTT cytotoxicity assay
was further employed to assess cell viability (Figure 7(d)).
Compared to the control, A1-AR agonist, CPA, at 100μM8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀects of cordycepin on the expression of StAR protein and StAR promoter activity in MA-10 mouse Leydig tumor cells. MA-10
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caused a signiﬁcant reduction in cell viability to 73.8 ± 5.2%
(P<. 05). A2A-AR agonist, CGS-21680, at 10μMa n d2 5μM
caused a signiﬁcant reduction in cell viability to 84.9 ±
2.4% and 78.4 ± 4.0%, respectively (P<. 05). A2B-AR
agonist, NECA, at 10μM and 100μM caused signiﬁcant
reductions in cell viability to 82.9 ± 1.5% and 72.9 ± 2.6%,
respectively (P<. 05). A3-AR agonist, IB-MECA, at 50μM
caused a signiﬁcant reduction in cell viability to 75.7 ± 2.4%
(P<. 05). These results showed that A1-, A2A-, A2B-, and
A3-AR agonists signiﬁcantly reduced MA-10 cell viability,
respectively (Figure 7(d))( P<. 05). Besides, cordycepin
alone (100μM and 1mM) signiﬁcantly decreased MA-10
cell viability approximately to 60% and 40%, respectively,
a f t e r2 4 h rt r e a t m e n t( Figure 7(e))( P<. 05). However,
A1-, A2A-, and A2B-AR agonists plus cordycepin treatments
did not have any additive eﬀects on MA-10 cell death,
respectively (Figure 7(e))( P>. 05). But, A3-AR agonist
(50μM) cotreated with cordycepin (100μM or1mM) would
reverse MA-10 cell viability back to 81.6 ± 9.6% or 61.6
± 7.8%, respectively (Figure 7(e)). These results showed
that A1-, A2A-, A2B-, and A3-AR might be very important
regarding the antitumor eﬀectsofcordycepininMA-10cells.
3.7. AR Antagonists Could Prevent Cordycepin-Induced Cell
Death in MA-10 Mouse Leydig Tumor Cells . In order to
conﬁrm whether cordycepin-induced apoptosis was medi-
ated via AR on MA-10 mouse Leydig tumor cells, cells were
treated with cordycepin (100μM and 1mM) plus A1-,A2A-,
A2B-, and A3-AR antagonists (DPCPX, Caﬀeine, MRS1754
and MRS1191) for 24hr, respectively. All A1-, A2A-, A2B,
and A3-AR antagonists could let cordycepin-treated MA-
10 cells recover back to polygonal shape, which is similar
to the cells in control group (Figure 8(a)). In MTT assay,
the cotreatment of 100μMc o r d y c e p i nw i t h1 μMA 1-,
A2A-, A2B-, and A3-AR antagonists could also signiﬁcantly
reverse cell viability to 90.6% ± 3.8%, 89.2% ± 4.8%,
86.7% ± 1.9% and 83.3% ± 5.7%., respectively (P<. 05)
(Figure 8(b)).However,thecotreatmentof1mM cordycepinEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: Eﬀects of cordycepin and adenosine on cell death in
MA-10 mouse Leydig tumor cells. MA-10 cells were cultured in
medium without or with adenosine (10μM∼10mM), 100μMa n d
1mM cordycepin for 48hr (a). MTT assay was performed to assess
cell viability. Data represent the mean ± SEM of four separate
experiments.Asterisk ∗(P<. 05)abovethebarsindicatessigniﬁcant
diﬀerence compared with control. (cordy. = cordycepin). (b) Gel
electrophoresis of a 1kb DNA ladder marker (lane M) or DNA iso-
lated from MA-10 cells that were cultured in the presence of 10mM
adenosine for 48hr. DNA was visualized by ethidium bromide
staining and photographed under UV illumination. Experiments
were performed four times (Exp. I–IV) with similarresults.
with A1-, A2A-, A2B-, and A3-AR antagonists did not reverse
cell viability (Figure 8(c)). These results indicate that the
apoptotic eﬀects of cordycepin on MA-10 cells could be
mediated by adenosine receptors.
4.Discussion
In this study, we demonstrate that cordycepin, a pure sub-
stance isolated from the Cordyceps sinensis, could stimulate
steroidogenesis inMA-10 mouse Leydig tumorcells. Besides,
cordycepin could induce the antitumor eﬀect possibly
through adenosine receptors in MA-10 mouse Leydig tumor
cells.
First, we found that cordycepin increased the expression
of A1-, A2A-, and A3-AR mRNAbutdecreased the expression
of A2B-AR mRNA at 24hr treatment. Under microscopic
observation, we found that cordycepin-treated MA-10 cells
exhibited cellular shrinkage and membrane blebbing, and
ﬁnally cells detached from the dish. By MTT and DNA
ladder assays, adenosine also signiﬁcantly reduced MA-10
cell viability in a dose-dependent manner and induced
DNA fragmentation. The eﬀective concentration (EC50) of
adenosine which could cause 50% inhibition of MA-10
c e l l sg r o w t hw a s5m Ma f t e r4 8h rt r e a t m e n t .H o w e v e r ,w e
observed that the death eﬀect of cordycepin was somewhat
greater than adenosine in the same concentration (100μM
and 1mM). These phenomena indicate that the apoptotic
eﬀect by adenosine in MA-10 cells was comparable.
Nakamura and coworkers havedemonstrated thatcordy-
cepin inhibited lung carcinoma cells and melanoma cells
growth by stimulating A3-AR [25, 26]. Many evidences have
also illustrated that A1-a n dA 2A-AR expression mediated
cell death by inducing apoptosis in breast carcinoma cells,
astrocytoma cells, mouse thymocytes [29–31]. In this study,
we showed that cordycepin could signiﬁcantly stimulate
the expression of A3-AR mRNA in cordycepin-treated MA-
10 cells. Moreover, this eﬀect also occurred in A1-AR and
A2A-AR mRNA expressions. In addition, we also demon-
strated that cordycepin induced MA-10 mouse Leydig tumor
cell apoptosis through caspase-9 and caspase-3 pathways
[28]. These data suggested that AR might participate in
cordycepin-induced apoptosis pathway in MA-10 mouse
Leydig cells.
We continued to investigate the AR agonists to cotreat
with cordycepin in MA-10 cells. We found that A3-AR
agonistscouldsignificantlyrescuecordycepin-inducedapop-
tosis in MA-10 cells. Many reports indicate that adenosine
displays contradictory eﬀects such as the induction of cell
apoptosis or stimulation of cell proliferation [32, 33]. It
has been reported that the A3-AR agonist (CL-IB-MECA)
reduced apoptosis in human astroglioma D384 cells [34]. In
fact, some evidences have shown that adenosine via A1-AR-
and A3-AR-mediated cytoprotection involves phospholipase
C, PKC, and p38 MAPK pathways, and reduced ROS
production in cardiomyocytes [35–37]. In this study, we
demonstrated that activation of AR would induce apoptosis
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Figure 7: A1,A 2A,A 2B,a n dA 3 AR were involved in cordycepin-induced cell death in MA-10 mouse Leydig tumor cells. MA-10 cells were
treated withA1,A 2A,A 2B,andA 3 ARagonistsintheabsenceorpresence ofcordycepin for24hr. (a)showsthat MA-10cells were incubated in
the absence or presence of cordycepin (100μM and 1mM) for 24hr. (b) shows that MA-10 cells were incubated in AR agonists (A1 100μM,
A2A 25μM, A2B 100μM, and A3 50μM) for 24hr. (c) shows that MA-10 cells were incubated in cordycepin (100μMo r1m M )p l u sA R
agonists (A1 10μM, A2A 10μM, A2B 10μM, and A3 50μM) for 24hr. Cell morphology was observed and recorded under light microscopy
(Olympus, CK 40). Note the same magniﬁcation (200x) among Figures. Arrowhead (
￿) indicates rounded-up cells and/or membrane-
blebbed cells. MA-10 cells (5,000 cells/well) were treated with diﬀerent dosages (1∼100μM) of A1-, A2A-, A2B-, and A3-AR agonist in the
absence(d)orpresence ofcordycepin (100μMand1mM)for24hr(e).MTTassaywasusedtoassesscellviability,whichwasproportionalto
absorbance at 590nm. Each data point in the Figure represents the mean the mean ± SEM of four independent experiments with triplicates
in each treatment. Asterisk ∗(P<. 05) above the bars indicates signiﬁcant diﬀerence compared with control. #(P<. 05) above the bars
indicates signiﬁcant diﬀerence compared with cordycepin alone treatment group (C: cordycepin).Evidence-Based Complementary and Alternative Medicine 11
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Figure 8: Eﬀects of AR antagonists on cordycepin-induced cell death in MA-10 mouse Leydig tumor cells. MA-10 cells were treated with
diﬀerent adenosine receptor antagonists in the absence or presence of cordycepin for 24hr. (a) shows that MA-10 cells were incubated
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microscopy (Olympus, CK 40). Note the same magniﬁcantion (200×) among Figures. Arrowhead (
￿) indicate rounded-up cells and/or
membrane-blebbed cells. MA-10 cells (5,000 cells/well) were treated with diﬀerent dosages (1∼100μM) of A1-, A2A-, A2B-, and A3-AR
antagonists in the presence of 100μM (b) or 1mM (c) cordycepin for 24hr. MTT assay was used to assess cell viability, which was
proportionalto absorbance at 590nm.Each data pointin the Figure represents the meanthe mean ± SEM offour independent experiments
with triplicates in each treatment. Asterisk ∗(P<. 05)above the bars indicates signiﬁcantdiﬀerence compared with control. #(P<. 05)above
the bars indicates signiﬁcantdiﬀerence compared with cordycepin alone treatment group (C: cordycepin).
AR could trigger apoptosis/survival pathway in MA-10 cells,
which must be further investigated.
Recent reports demonstrated that adenosine receptor
antagonists can resume cell viability on toxicant drug-
induced apoptosis in thyroid cancer cells [38, 39]. We used
the selective AR antagonists to cotreat with cordycepin in
MA-10 cells. We also demonstrated that A1-,A2A-,A2B-,
and A3-AR antagonist could signiﬁcantly rescue 100μM
cordycepin-induced apoptosis in MA-10 cells. These results
indicate that the apoptotic eﬀects of cordycepin on MA-10
cells could be mediated by AR. However, 1mM cordycepin
cotreated with adenosine antagonists could not reverse cell
viability, but even promote cell death. Recent developments
of potent and selective antagonists of AR subtypes have
been valuable for further deﬁning the physiological eﬀects
of the various AR subtypes. Moreover, there are substantial
species diﬀerences in the aﬃnity of these compounds, and
these selective compounds may fairly potent as antagonists
of another AR subtypes [40].
It has been shown that adenosine-stimulated steroido-
genesis might be involved in the A2A-a n dA 2B-AR and
phosphorylation of MAPK ERK 1/2 signal pathway in rat
adrenal cells [41]. Moreover, it is proposed that ligand
binding results in a change in receptor state from an inactive
to an active state will ultimately elicit its biological response
based on the receptor’s conformation [42]. In this model,12 Evidence-Based Complementary and Alternative Medicine
agonists are thought to have selective binding aﬃnity for
the preexisting resting and active states or can induce a
conformational change to a diﬀerent receptor state and
eﬀects binding aﬃnity of a ligand [43]. In the present
study, cordycepin cotreated with A2B-AR agonist (NECA)
would signiﬁcantly decrease NECA-stimulated progesterone
production. It is probable that cordycepin may bind with
other receptors and induce conformation change to eﬀect
binding aﬃnity of A2B-AR agonist. This result is consistent
with the observationthat cordycepin(100μM) decreased the
expression of A2B-AR mRNA at 24hr treatment. Although
cordycepin (100μM) did not aﬀect the expression of A1-
and A3-AR mRNA, cordycepin cotreated with A1-a n dA 3-
AR agonist (CPA and IB-MECA) also signiﬁcantly decreased
their progesterone production. On the other hand, cordy-
cepin did not aﬀect the A2A-AR agonist (CGS-21680)-
stimulated progesterone production. It is reasonable that
cordycepinmaycompetewithCGS-21680inthesame biding
site of A2A-AR to stimulate progesterone production. Here,
we demonstrated that activation of A1-, A2A-, A2B-, and
A3-AR could induce steroidogenesis in MA-10. However,
we used the AR antagonists to cotreat with cordycepin,
and results illustrated huge variations. AR antagonists only
slightly increased progesterone production than control
group in MA-10 cells, which may decrease the accuracy.
More experiments should be conducted to decrease the
inconsistence.
Steroid production in Leydig and granulosa cells are reg-
ulated by various factors, including cAMP/PKA-dependent
[44], mitogen-activated protein kinase/extracellular signal-
regulated kinase 1/2 (MAPK ERK 1/2) [45, 46], and protein
kinase C (PKC) signaling pathways [47, 48]. These kinases
modulate cellular processes by phosphorylations. The family
of MAPKs includes extracellular regulating kinase (ERK),
c-Jun NH(2)-terminal kinase (JNK), and p38, with each
MAPK signaling pathway consisting of at least three com-
ponents, a MAPK kinase kinase (MAP3k), a MAPK kinase
(MAP2k), and a MAPK. Some reports have shown the
stimulatory eﬀectsofMAPK ERK1/2onsteroidogenesis[49,
50], and the others have demonstrated the inhibitory eﬀects
on steroidogenesis [51, 52]. PKC signaling pathway can be
activated by signals such as increases in the concentration of
diacylglyceride(DAG),phospholipaseC(PLC),orCa2+ [53].
Recent reports indicate that DAX-1 gene interplay between
the PKA/PKCsignaling pathways and represses expression of
StAR protein and steroidogenesis [54].
It is well established that StAR protein is essential for
steroidogenesis, and that ERK 1/2 phosphorylation driven
by mitochondrial PKA will induce StAR protein expression
and then steroidogenesis [46]. The previous data showed
that cordycepin upregulates the expression of StAR mRNA
and StARprotein to induce steroidogenesis through the PKA
signaling pathway in normal mouse Leydig cells [55]. It
has also been documented that the downstream eﬀectors of
PKA signaling pathway include several transcription factors
[56]. However, our results indicated that cordycepin could
not induce StAR protein and StAR promoter expressions in
MA-10 cells. Our data are somewhat inconsistent to several
studies that steroidogenesis could be trigger by cAMP and
StAR-independentpathways[57–59].Therefore,itispossible
that the cordycepin could possibly acitvate MAPK-ERK 1/2
and PKC pathways without increasing of StAR promoterand
StAR protein expression to induce steroidogenesis in MA-10
cells, which will be worth to further investigate.
In conclusion, the present studies demonstrate that
cordycepin is one of the active constituent of Cordyceps
sinensis, which can stimulate progesterone production in
MA-10 cells. Meanwhile, cordycepin could also activate AR
and simultaneously induce steroidogenesis and apoptosis in
MA-10 mouse Leydig tumor cells.
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